Mechanism of Disease | gMG NEVER RESTS

SEE THE ROLE OF BOTH AChR & MuSK
AUTOANTIBODIES IN gMG

gMG is caused by pathogenic immunoglobulin G (IgG) autoantibodies that
target components of the neuromuscular junction (NMJ). The two main
types of autoantibodies target either acetylcholine receptors (AChR) or
muscle-specific kinase (MuSK).^17-20

UP TO 88%

AChR autoantibodies

ARE DETECTED IN PATIENTS WITH gMG^17-19

10-15%

MuSK
AUTOANTIBODIES

ARE DETECTED IN PATIENTS WITH gMG²⁰

EXPLORE HYPOTHETICAL AChR+ AND MuSK+ PATIENT PROFILES

VIDEO GUIDE

0:00 - :45 gMG overview, symptoms, and daily impact

0:46- :55 The prevalence of uncontrolled disease

0:56 - 1:12 Non-autoantibody specific MOD overview

1:13 - 1:46 The prevalence of AChR, MuSK and LRP4 autoantibodies in MG

1:47 - 2:20 AChR+ MOD: AChR autoantibody binding and resulting complement activation interrupt normal synaptic function

2:21 - 2:50 Complement: one of the main causes of NMJ destruction

2:51- 3:13 MuSK+ MOD: MuSK autoantibodies cause loss of acetylcholine receptors, resulting in muscle weakness

3:14 - 3:38 The role of endothelial cell recycling of antibodies

3:39 - 3:51 Long-term side effects of conventional treatments

3:52 - 4:05 A message from UCB

Learn how to identify uncontrolled gMG >

By providing this information, you are giving UCB and its business partners permission to send you information regarding this disease and treatments. You understand that UCB or its business partners will not sell your name, address, email address, or any other information to another party for their own marketing use. You may remove yourself from the mailing list at any time by unsubscribing. View our Privacy Policy.

Top

Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60(6):707-715.
Tran C, Biswas A, Mendoza M, Katzberg H, Bril V, Barnett C. Performance of different criteria for refractory myasthenia gravis. Eur J Neurol. 2021;28(4):1375-1384.
Petersson M, Feresiadou A, Jons D, et al. Patient-reported symptom severity in a nationwide myasthenia gravis cohort. Neurology. 2021;97:e1382-e1391.
Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141-149.
Silva, P. MG patients satisfied with treatment, but quality of life could be better, US survey shows. Myasthenia Gravis News. June 17, 2021. Accessed April 14, 2022. https://myastheniagravisnews.com/news-posts/2021/06/17/mg-patients-want-better-quality-of-life-us- survey-shows/?cn-reloaded=1
Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C. Patient-acceptable symptom states in myasthenia gravis. Neurology. 2020;95(12):e1617-e1628.
Xin H, Harris LA, Aban IB, Cutter G. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America patient registry sample. J Clin Neurol. 2019;15(3):376-385.
Data on file. Ra Pharma, 2018.
Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.
Lee I, Kaminkski H, McPherson T, et al. Gender differences in prednisone adverse effects Survey result from the MG registry. Neurol Neuroimmunol Neuroinflamm. 2018; 5:e507.
Werneck LC, Scola RH, Germiniani FM, Comerlato EA, Cunha FM. Myasthenic crisis: report of 24 cases. Arq Neuropsiquiatr. 2002;60(3-A):519-526.
Andersen L, Jakobsson A, Revsbech, K, Vissing J. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol. Published online November 21, 2021. doi:10.1007/s00415-021-10902-1
Baggi F, Andreetta F, Maggi L, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology. 2013;80(2):188-195.
Imai T, Utsugisawa K, Murai H, et al. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. J Neurol Neurosurg Psychiatry. 2018;89(5):513-517.
Kaminski HJ, Kusner LL. Myasthenia Gravis and Related Disorders. 3rd ed. Humana Press. 2018.
Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22(7):1164-1169.
Anil R, Kumar A, Alaparthi S, et al. Exploring outcomes and characteristics of myasthenia gravis: rationale, aims and design of registry–the EXPLORE-MG registry. J Neurol Sci. 2020;414:116830.
Lindstrom J, Seybold M, Lennon V, et al. Antibody to acetylcholine receptor in myasthenia gravis. Neurology. 1976;26:1054-1059.
Vincent A, Newson-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985;48:1246-1252.
Burden SJ, Yumoto N, Zhang W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol. 2013;5(5):a009167.
Nagane Y, Murai H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7(2):e013278.
Nowak RJ. Myasthenia gravis: challenges and burdens of disease. Neurology Reviews. March 2018. Accessed April 2022. https://www.neurologyreviews-digital.com/neurologyreviews/nord_supplement_0318/MobilePagedArticle.action articleId=1361082#articleId1361082
The CIE. The cost to patients and the community of Myasthenia Gravis. Centre for International Economics; November 2013. Accessed May 1, 2022. http://www.thecie.com.au/wp-content/uploads/2014/06/Final-report_Economic-Impact-of-Myasthenia-Gravis-08112013.pdf
Twork S, Wiesmeth S, Klewer J, Pöhlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.
Ruiter A, Verschuuren J, Tannemaat M. Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromuscular Disorders. 2020;30(8):631-639.
Stewart SB, Roberston KR, Johnson KM, Howard JF Jr. The prevalence of depression in myasthenia gravis. J Clin Neuromusc Dis. 2007;8(3):111-115.
Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve. 2019;60(6):700-706.
Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.
Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570-2581.
Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin. 2018;36(2):311-337.
Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19(1):335.